ConSynance Initiates Toxicology Studies on CSTI-300 for Irritable Bowel Syndrome

09:15 EDT 29 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
ConSynance Therapeutics, Inc. announced today that it has initiated a series of toxicology studies for CSTI-300, its drug candidate for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Successful completion and r...

Other Sources for this Article

ConSynance Therapeutics, Inc.
Shuang Liu, PhD, 518-275-0176


More From BioPortfolio on "ConSynance Initiates Toxicology Studies on CSTI-300 for Irritable Bowel Syndrome"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...